Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Peer Review reports

Original Submission
22 Apr 2022	Submitted	Original manuscript
13 May 2022	Author responded	Author comments - Bernard Jan Smilde
Resubmission - Version 2
13 May 2022	Submitted	Manuscript version 2
Publishing
24 May 2022	Editorially accepted
1 Jun 2022	Article published	10.1186/s12891-022-05471-x

Back to article page